Abstract

Aliskiren is a novel renin inhibitor that is prescribed for the treatment of hypertension. This short and elegant synthesis features the construction of a nine-membered ring by ring-closing metathesis to give B followed by an acid-catalyzed rearrangement of the aziridine C to give pyrrolidine D in 81% yield.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.